Moderna, Inc. and CytomX Therapeutics, Inc., a leader in the field of conditionally activated oncology therapeutics, entered a collaboration and licensing agreement to create investigational mRNA-based conditionally activated therapies using Moderna’s mRNA technologies and CytomX’s Probody therapeutic platform.   The research collaboration will leverage Moderna’s mRNA platform that has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncolo...